MBX Biosciences, Inc. (MBX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US55287L1017
MBX Biosciences, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -98.06 m USD |
| EBIT | -86.97 m USD |
| Net income | -86.97 m USD |
| Diluted EPS – continuing operations | -2.38 USD |
Full history since 2022, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
More stocks
- Lechwerke (LEC.F)
- Henan Huanghe Whirlwind Co Ltd (600172.SS)
- Noah Holdings Ltd (NOAH)
- Urban Edge Properties (UE)
- HgCapital Trust PLC (HGT.L)
- Payoneer Global Inc. (PAYO)
- CECONOMY (CEC.DE)
- Xiamen Intretech Inc Class A (002925.SZ)
- XD Inc (2400.HK)
- DO & CO AG (DOC.VI)
- Sunway Construction Group Bhd (5263.KL)
- Runjian Communication Co Ltd Class A (002929.SZ)
Not investment advice. All data without warranty, price as of 23.10.2026. Details in the risk notice.